Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system
| No. | 75 |
|---|---|
| Citation | Blood Adv 4 (21): 5501-5511(2020) |
| Institute | Hamamatsu University School of Medicine |
| 1st Author | Y Suzuki |
| AR | 〇 (240/s) |
| PL | |
| HD | |
| Paper types | Basic research |
| Main purpose | Evaluation of the role of thrombin-activatable fibrinolysis inhibitor (TAFI) |
| Disease | |
| Antiplatelet drug | |
| Anticoagulant drug | |
| Other drug | tPA, TAFIa inhibitor |
| Clinical specimens | |
| Animal | |
| Keyword | tissue-type plasminogen activator, tPA, thrombin-activatable fibrinolysis inhibitor, TAFI |